November 15th, 2026Dr Dasari on Sequencing RLT, Cabozantinib, and Everolimus in NETsArvind Dasari, MD, MS, explains how to sequence radioligand therapy, cabozantinib, and everolimus in well-differentiated neuroendocrine tumors.Read more
November 12th, 2026Dr Iyer on AI Documentation and Tumor Boards in Neuroendocrine TumorsRenuka Iyer, MD, discusses clear documentation for AI ambient scribes and why multidisciplinary tumor boards remain essential in neuroendocrine tumor care.Read more
November 12th, 2026Dr Chauhan on DLL3 Expression and Obrixtamig Outcomes in DAREON-7Aman Chauhan, MD, reviews DAREON-7 data on obrixtamig plus chemotherapy in DLL3-positive neuroendocrine carcinoma, including response rates by DLL3 level.Read more
November 8th, 2026Dr Dasari on Emerging PRRT Options and New Therapeutic Targets in NETsArvind Dasari, MD, MS, reviews key advances in neuroendocrine tumors, including new PRRT options, alpha emitters, cabozantinib, and clinical trials.Read more
November 7th, 2026Dr Chauhan on Oncolytic Virus SVV-001 Plus Ipi/Nivo in Neuroendocrine CancersAman Chauhan, MD, discusses combining intratumoral Seneca Valley virus (SVV-001) with ipilimumab and nivolumab in neuroendocrine cancer.Read more
November 7th, 2026Dr Trikalinos on Cabozantinib in Functional and Nonfunctional NETsNikolaos Trikalinos, MD, reviews CABINET data showing cabozantinib improved PFS in functional and nonfunctional NETs without added grade 3 toxicity.Read more